ABT vs STE: fair value comparison
Abbott Laboratories and STERIS plc · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, STE currently sits closer to the top of our discount ranking. STE carries the stronger quality grade.
| ABT | STE | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $112.47 | $233.78 |
| 12-month range | $87.78–$131.46 | $211.07–$264.24 |
| Sector rank | #43 of 113 Healthcare | #38 of 113 Healthcare |
| Quality grade | B | A |
| Momentum grade | — | A |
| Leverage | Low | Low |
| Margin trend | Expanding | Expanding |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Overvalued | Overvalued |
| 52-week position | The upper-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: ABT fair value analysis · STE fair value analysis